Search

Displaying results 4251 - 4260 of 7063 in total
  1. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    Depemokimab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody and a long-acting drug. … [A275338] Depemokimab blocks interleukin-5 (IL-5), a key cytokine that regulates eosinophil maturation, survival, and recruitment.

  2. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    Chlormadinone acetate is a progesterone derivative first synthesized in 1961. … In 1972, the FDA withdrew its approval for the use of chlormadinone acetate in all products.

  3. Drug

    Tadalafil

    go.drugbank.com/drugs/DB00820
    ApprovedInvestigational

    In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment … [L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH.

    Products: N/a, TADAL 1A PHARMA PAH 20MG
  4. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    Zongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). … [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain

  5. Drug

    Bezafibrate

    go.drugbank.com/drugs/DB01393
    ApprovedInvestigational

    Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.

    Products: BEZAFIBRAT 400 RET 1A PHAR, Bezafibrat Genericon retard 400 mg Filmtabletten
  6. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    [L10241] In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs). … Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    Zolmitriptan

    go.drugbank.com/drugs/DB00315
    ApprovedInvestigational

    Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine. … [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.

    Categories: Monoamine Oxidase A SubstratesProducts: ZOLMITRIPTAN 1A PHAR 5MG, ZOLMITRIPTAN 1A PHAR 2.5MG
  8. Drug

    FLT190

    go.drugbank.com/drugs/DB18420
    Investigational

    FLT190 is a recombinant adeno-associated viral vector serotype S3 containing DNA encoding for human alpha-galactosidase A.

  9. Drug

    Recanaclotide

    go.drugbank.com/drugs/DB15417
    Investigational

    Recanaclotide is under investigation in clinical trial NCT01712412 (Phase 2a Study of IW-9179 to Treat Functional Dyspepsia).

  10. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    [L10145] The FDA approved Selinexor in June 2019. … Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound.